1887
Rapid communication Open Access
Like 0

Abstract

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2024.29.8.2400089
2024-02-22
2024-12-21
/content/10.2807/1560-7917.ES.2024.29.8.2400089
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/29/8/eurosurv-29-8-1.html?itemId=/content/10.2807/1560-7917.ES.2024.29.8.2400089&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC). European Respiratory Virus Surveillance Summary (ERVISS), 2024, Week 05. Stockholm: ECDC. [Accessed: 16 Feb 2024]. Available from: https://erviss.org
  2. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season
  3. European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler. Stockholm: ECDC. [Accessed: 31 Jan 2024]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=15&SelectedCountryIdByDisease=-1
  4. European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC studies of vaccine effectiveness against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection at primary care level: version 1.0, September 2023. Stockholm: ECDC; 2023. Available from: https://data.europa.eu/doi/10.2900/25966
  5. European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC VEBIS studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or seasonal influenza - Version 2.0. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-vaccine-effectiveness-sari-protocol-version-2.pdf
  6. Covenay J. FIRTHLOGIT: Stata module to calculate bias reduction in logistic regression. Boston: Boston College Department of Economics; 2015. Available from: https://EconPapers.repec.org/RePEc:boc:bocode:s456948
  7. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, Summary Europe, December 2023. Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/influenza-ECDC-WHO-Report-december-2023.pdf
  8. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, Summary Europe, August 2023. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Influenza-characterization-August-2023.pdf
  9. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season. Geneva: WHO. [Accessed: 3 Feb 2023]. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-2023-northern-hemisphere-influenza-season
  10. Skowronski DM, Zhan Y, Kaweski SE, Sabaiduc S, Khalid A, Olsha R, et al. 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN). Euro Surveill. 2024;29(7):2400076.  https://doi.org/10.2807/1560-7917.ES.2024.29.7.2400076  PMID: 38362622 
  11. Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Oroszi B, et al. Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study. Influenza Other Respir Viruses. 2024;18(1):e13243.  https://doi.org/10.1111/irv.13243  PMID: 38204584 
  12. Rose A, Pozo F, Martínez-Baz I, Mazagatos C, Bossuyt N, Cauchi JP, et al. Vaccine effectiveness against influenza hospitalisation in adults during the 2022/23 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network. Influenza Other Respir Viruses. 2024;18(2).  https://doi.org/10.1111/irv.13255 
  13. Smolarchuk C, Ickert C, Zelyas N, Kwong JC, Buchan SA. Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season. Euro Surveill. 2024;29(2):2300709.  https://doi.org/10.2807/1560-7917.ES.2024.29.2.2300709  PMID: 38214082 
/content/10.2807/1560-7917.ES.2024.29.8.2400089
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error